My Cart

SB 216763

Potent and selective GSK3 inhibitor (Ki= 9 nM for GSK-3α). Has little activity against 24 other protein kinases (IC50 > 10 μM). Stimulates glycogen synthesis, gene transcription and is cardio- and neuroprotective.

Grouped product items
SKUSIZEPRICE QTY
SML31A5 mg
$150.00
- +
SML31B10 mg
$250.00
- +
Details
Resources
Reviews
Description
Specifications
More Information
SKUSML31
Molecular NameSB 216763
FormPowder
Alternative NamesSB216763, SB-216763
Chemical Name3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
Chemical FormulaC19H12Cl2N2O2
Molecular Weight371.22
CAS Number280744-09-4
PubChem ID176158
Purity≥98% (LCMS)
Physical AppearanceOrange to red
TargetGSK-3; Autophagy
ShippingAMB

SB 216763 is a potent and selective, ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor. Equally effective at inhibiting human GSK-3α and GSK-3β. Exhibits minimal activity against 24 other protein kinases (IC50 >10 μM). Stimulates glycogen synthesis in liver cells and induces β-catenin-dependent gene transcription. Neuroprotective; also reduces pulmonary inflammation and fibrosis in a mouse model. Shown to maintain mouse embryonic stem cells in a pluripotent state.

SB 216763 maintains mouse embryonic stem (ES) cells in an undifferentiated, pluripotent state for up to two months when co-cultured with mouse embryonic fibroblasts (MEFs) in the absence of leukemia inhibitory factor (LIF; Kirby et al.) and increases neural progenitor proliferation in mouse brains (Mao et al.). SB 216763 has been found to induce differentiation and reduce the cancer stem cell population of cultured human glioblastoma cells (Korur et al.).

Alternative names: GSK-3 Inhibitor IV, SB-216763, SB-216763
Applications: Differentiation, Expansion, Maintenance
Cell types: Cancer Cells and Cell Lines, Dendritic Cells, Hematopoietic Stem and Progenitor Cells, Mesenchymal Stem and Progenitor Cells, Myogenic Stem and Progenitor Cells, Neural Stem and Progenitor Cells, Pluripotent Stem Cells

Resources
References & Publications
  • Cell Res. 2022 Jun;32(6):513-529
  • Nat Commun. 2022 Apr 19;13(1):2105.
  • Theranostics. 2019 Aug 12;9(20):5769-5783.
  • Haematologica. 2020 Mar;105(3):661-673.
  • Br J Cancer. 2023 Jan 30.
  • Gurrieri, et al. J.Pharmacol.Exp.Ther. 2010
  • Kirby LA, et al. PLoS One. 2012;7(6):e39329. Epub 2012
Reviews
Write Your Own Review
You're reviewing:SB 216763
Your Rating